Skip to content
Open access

AAV-mediated CBLN1 replacement rescues hereditary ataxia caused by biallelic CBLN1 variants.

Sep 2026 · Molecular Therapy · 0 citations
Medicine

TL;DR

These findings establish CBLN1 deficiency as a cause of hereditary ataxia and identify extracellular CBLN1 replacement as a therapeutic strategy for a reversible cerebellar synaptopathy.

Abstract

Cbln1 is a secreted synaptic organizer required for parallel fiber-Purkinje cell (PF-PC) synapse integrity, climbing fiber (CF) refinement, and cerebellar motor learning, but has not previously been implicated in human disease. We identified biallelic CBLN1 missense variants (A63P and Y112C) in two unrelated families with early-onset cerebellar ataxia accompanied by oculomotor abnormalities, cerebellar atrophy, and variable cognitive delay. In heterologous cells, both variants showed reduced steady-state protein abundance, impaired maturation through the early secretory pathway, and little or no detectable secretion, resulting in markedly reduced extracellular CBLN1 availability. Consistently, cerebellar granule cells expressing CBLN1-Y112C failed to induce excitatory synapses onto glutamate receptor δ2 (GluD2)-expressing cells in vitro. A knock-in mouse harboring Y112C lacked synaptic Cbln1 and recapitulated key features of Cbln1 deficiency, including disrupted PF-PC synapse organization, persistent CF multi-innervation, impaired PF-PC transmission and long-term depression, and deficits in motor coordination and oculomotor learning. Notably, systemic delivery of an astrocyte-targeted adeno-associated virus expressing wild-type CBLN1 in adult mutant mice restored synaptic CBLN1 localization, cerebellar synaptic function, plasticity, and behavior. These findings establish CBLN1 deficiency as a cause of hereditary ataxia and identify extracellular CBLN1 replacement as a therapeutic strategy for a reversible cerebellar synaptopathy.

Read PDF

Similar papers

Open access Sep 2026

AAV-mediated SIL1 gene therapy prevents cerebellar degeneration and ataxia in a mouse model of Marinesco-Sjögren syndrome

Findings provide proof-of-principle that AAV-mediated SIL1 gene therapy can prevent the neurological and muscular manifestations of Marinesco-Sjögren syndrome and identify Purkinje cells as a critical cellular target for preventing cerebellar dysfunction.

Chiara Pasini, Giada Lavigna, Anna Grasso et al. · 0 citations
#gene editing Open access Sep 2026

Pathogenic KIF1A variants differentially disrupt axonal trafficking and impede synaptic development

Functional analysis of neuronal activity reveals delayed synaptic maturation in loss-of-function mutations and insights into how KIF1A mutations with distinct molecular-level impacts lead to significant downstream synaptic deficits in human neurons.

Jayne Aiken, Carris Borland, Nicolas Marotta et al. · 0 citations
Open access Aug 2026

Ficd loss rescues motor impairments and reverses oligodendrocyte maturation deficits in a mouse model of spinocerebellar ataxia type 3

It is demonstrated that Ficd deletion mitigates the pathological decrease in myelin structural proteins and oligodendrocyte maturation factors, restoring levels of mature, myelinating oligodendrocytes and identifies FICD as a novel target for alleviating non-neuronal toxicity in SCA3.

K. V. Van Pelt, Ya-Mei Deng, A. Nesvizhskii et al. · 0 citations
Open access Aug 2026

Modeling and targeting haploinsufficiency in SHINE syndrome

These findings establish DLG4 haploinsufficiency as a shared consequence of pathogenic DLG4 variants, while revealing additional variant-associated effects on neuronal structure and activity, rescued by AAV9-mediated neuronal restoration.

Dania Abdellatif, Mustafa Obeid, Rami I. Aqeilan · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.